142 related articles for article (PubMed ID: 38581458)
1. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
[TBL] [Abstract][Full Text] [Related]
2. Expression level of BTN3A1 on the surface of CD14
Tomogane M; Omura M; Sano Y; Shimizu D; Toda Y; Hosogi S; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():47-54. PubMed ID: 34952469
[TBL] [Abstract][Full Text] [Related]
3. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
Castella B; Riganti C; Fiore F; Pantaleoni F; Canepari ME; Peola S; Foglietta M; Palumbo A; Bosia A; Coscia M; Boccadoro M; Massaia M
J Immunol; 2011 Aug; 187(4):1578-90. PubMed ID: 21753152
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Immunology; 2014 Dec; 143(4):539-49. PubMed ID: 24912747
[TBL] [Abstract][Full Text] [Related]
5. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
6. [The comparison between HIV-infected patients' Vdelta2 T cells expansion efficiencies by zoledronic acid and gammadelta TCR monoclonal antibody in vitro].
Xu W; Wu XL; Xie YX; Yang JL; Nie WM; Zhao M; Chen WW
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Dec; 26(6):442-5. PubMed ID: 23627025
[TBL] [Abstract][Full Text] [Related]
7. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
[TBL] [Abstract][Full Text] [Related]
8. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M
J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919
[TBL] [Abstract][Full Text] [Related]
9. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
10. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
Serrano R; Wesch D; Kabelitz D
Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
[TBL] [Abstract][Full Text] [Related]
11. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
[TBL] [Abstract][Full Text] [Related]
12. Activation of human γδ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin.
Rhodes DA; Chen HC; Price AJ; Keeble AH; Davey MS; James LC; Eberl M; Trowsdale J
J Immunol; 2015 Mar; 194(5):2390-8. PubMed ID: 25637025
[TBL] [Abstract][Full Text] [Related]
13. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
16. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
17. IL-12 conditioning of peripheral blood mononuclear cells from breast cancer patients promotes the zoledronate-induced expansion of γδ T cells in vitro and enhances their cytotoxic activity and cytokine production.
Assy L; Khalil SM; Attia M; Salem ML
Int Immunopharmacol; 2023 Jan; 114():109402. PubMed ID: 36481526
[TBL] [Abstract][Full Text] [Related]
18. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
[TBL] [Abstract][Full Text] [Related]
19. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
[TBL] [Abstract][Full Text] [Related]
20. Expansion of Th
Harada T; Miki H; Cui Q; Oda A; Amachi R; Teramachi J; Bat-Erdene A; Sogabe K; Iwasa M; Fujii S; Nakamura S; Kagawa K; Yoshida S; Endo I; Aihara K; Ozaki S; Matsumoto T; Abe M
Leukemia; 2017 Jan; 31(1):258-262. PubMed ID: 27698446
[No Abstract] [Full Text] [Related]
[Next] [New Search]
